CytomX Therapeutics, Inc.

As of June 30, 2026, CytomX Therapeutics, Inc. carries a market capitalization of 717.54M, placing it among publicly traded companies globally. Its enterprise value stands at 433.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CytomX Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, CytomX Therapeutics, Inc. has 217.90M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 37.59, and the price-to-book ratio stands at 2.71.

These figures are as of June 30, 2026. The EV/Sales ratio of 27.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 433.44M versus a market cap of 717.54M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CytomX Therapeutics, Inc. maintains a current ratio of 9.36, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, CytomX Therapeutics, Inc. posted a negative return on equity (ROE) of -37.75, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.64, reflecting losses generated across the asset base. The company generates approximately 195,362.69 in revenue per employee across its workforce of 82.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, CytomX Therapeutics, Inc. recorded 202,194.30 in income tax expense. The company reported a pretax loss of -69.52M and -69.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, CytomX Therapeutics, Inc.'s stock has declined approximately 26.47% over the past 52 weeks. The 50-day moving average sits at 2.59, while the 200-day moving average is 3.38.

Over the twelve months ended June 30, 2026, CytomX Therapeutics, Inc. generated 16.02M in revenue and converted that into -69.72M in net income, yielding earnings per share of -0.38. EBITDA reached -75.46M, while operating income came in at -76.29M.

As of June 30, 2026, CytomX Therapeutics, Inc. holds 289.09M in cash and equivalents against 4.99M in total debt, resulting in a net debt position of -15.08M. Total book value stands at 264.40M, with working capital of 291.73M providing operational flexibility.

CytomX Therapeutics, Inc. produced -72.13M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -64,772.20 in capital expenditures, free cash flow totaled -72.20M - equivalent to -0.39 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -476.19 and net profit margin of -435.21 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -30.73, meaning CytomX Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, CytomX Therapeutics, Inc. has an Altman Z-Score of 3.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.